Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

Benzinga · 1d ago
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.